PRESS RELEASE

FAE TECHNOLOGY GROUP: KAYSER SPACE ON THE FRONT LINES OF THE ASTROBONE SCIENTIFIC EXPERIMENT, WHICH SEEKS TO TEST BONE THERAPIES IN MICROGRAVITY

The mission was launched from Cape Canaveral Space Force Station and reached the International Space Station yesterday aboard the SpaceX CRS-34 flight

Kayser Space developed and implemented the experiment's mission systems: sixteen experiment units to be installed in the KUBIK incubator, which was developed by Comat in collaboration with Kayser Space and is operated in the European Space Agency's Columbus module

Gazzaniga (BG), May 18, 2026 – FAE Technology S.p.A. – Benefit Company ("**FAE Technology**" or the "**Company**"), the high-tech industrial group which designs, engineers and produces advanced electronics-based systems for high-reliability terrestrial and space markets (the "**Group**"), through its subsidiary **Kayser Space**, is a key player in the Astrobone scientific experiment that was launched from Cape Canaveral Space Force Station in Florida, USA aboard the SpaceX CRS-34 transport mission, which reached the International Space Station yesterday. The goal of the Astrobone experiment is to test in microgravity the clinical application of b.Bone, an innovative biomimetic bone substitute developed by GreenBone Ortho S.p.A., a Roncadelle-based company that specializes in the field of bone regeneration to treat osteoporosis-related bone defects.

Specifically, Kayser Space designed and built the experiment units that house the scaffold, the three-dimensional model that provides support for cell growth. The 16 units constitute the operational infrastructure of the experiment. They consist of systems equipped with a culture chamber and power modules, which are essential in ensuring the survival, growth and monitoring of cells - in this case, mesenchymal stem cells - in space.

The experiment forms part of FAE Technology's strategy to consolidate its presence in the Space sector through Kayser Space, which focuses on technological development and support for space research and exploration programs. Against this backdrop, Astrobone represents an opportunity to strengthen the Group's positioning in microgravity applications and high value-added services in the area of space science

research. This will, in turn, facilitate access to programs with potential commercial applications in the New Space economy and consolidate the Group's presence in a sector marked by strong technological and industrial growth.

Gianmarco Lanza, Chairperson of Kayser Italia, and Chairperson and Chief Executive Officer of FAE Technology, states: "*This experiment is an effective demonstration of Kayser Space's contribution to microgravity research programs. It not only strengthens the Group's track record on in-orbit missions, but also makes a concrete contribution to scientific activities in terms of the actual value of its application, results and publications, and will have spin-off effects in both space and terrestrial environments. Kayser Space's experience in space exploration, combined with the Group's industrial expertise, mean we can strengthen our position in the space economy through a model that is increasingly oriented toward the development of low-orbit applications and commercial opportunities. Being directly involved in missions also contributes to bringing us closer in practice to space activities and ensures that our staff are heavily involved*".

David Stefano Zolesi, Chief Executive Officer of Kayser Italia and Director of the Space Division of the FAE Technology Group, states: "*Our role in this scientific mission consolidates Kayser Space's role as a leading partner in the development of critical infrastructure for microgravity research. Our contribution goes beyond simply providing state-of-the-art hardware - it extends to full-service management. Through the Bioreactor Express program, which is based on the KUBIK incubator aboard the ISS, we offer direct and simplified access to on-board facilities, turning technology into a turnkey operational solution for researchers. By bringing together engineering excellence and life sciences support services, we are able to perform a new generation of invaluable experiments, with concrete knock-on effects for both clinical medicine on Earth and the future frontiers of space exploration*."

The Dragon spacecraft was launched aboard SpaceX's Falcon 9 launch vehicle, which is hosting the experiment, on Friday, May 15 at 6:05 p.m. ET (12:05 a.m. on Saturday, May 16, Italian time) from Launch Complex 40 (SLC-40) at Cape Canaveral Space Force Station. After an approximately 36-hour flight, Dragon autonomously docked with the International Space Station on Sunday, May 17 at 6:37 a.m. ET (12:37 p.m. Italian time).

The experiment units were installed inside KUBIK, an incubator developed by COMAT with contributions from Kayser Space and operated within the European Space Agency's (ESA) Columbus module. The system will allow the experiment to be performed for around a month at a constant and controlled temperature. Microgravity conditions will be in place for 50% of the experiment units and Earth gravity will be used for the other half, which will be placed on a centrifuge built into the incubator.

The experiment seeks to test whether human bone cells retain the ability to adhere, proliferate and differentiate on the scaffold in conditions of microgravity, providing key evidence for the clinical use of b.Bone. The results may have impacts both on Earth - for

the treatment of osteoporosis - and in space, where astronauts suffer up to 2% accelerated bone loss per month. To counteract this, they must exercise for around two and a half hours a day, six days a week.

Once they leave orbit, the samples will be brought back to Earth and analyzed by the joint team from San Martino Hospital and the University of Genoa. The first scientific results are expected within a year.

B.Bone
b.Bone is a resorbable bone substitute developed by GreenBone Ortho S.p.A., a company with offices in Faenza (RA) and Roncadelle (BS). It is made from rattan, a Southeast Asian plant whose three-dimensional structure is naturally similar to that of human bone. Through a patented biomorphic transformation process, the plant material is converted into a biomimetic calcium phosphate, while preserving its porous architecture, creating a bioactive matrix that can support bone regeneration processes. The mechanisms of cellular infiltration, proliferation and differentiation are currently being investigated - first in the laboratory and now in space aboard the International Space Station - through advanced biological, molecular and microscopic analyses.

****

For the dissemination of regulated information FAE Technology uses the 1INFOSDIR dissemination system (www.1info.it) operated by Computershare S.p.A., with registered office in Milan, Via Lorenzo Mascheroni No. 19 and authorized by Consob.

This Press Release is available in the Investors Relations/Press Releases section of the website https://fae.technology/and at www.1info.it.

****

FAE Technology S.p.A. - Benefit Company is a high-tech industrial Group listed on the Euronext Growth Milan market and engaged in the design, engineering and production of advanced electronics-based systems for high-reliability terrestrial and space sector markets. Through the Electronics Division, the Group operates as an Original Design Manufacturer (ODM) and comprises several highly-specialized companies: FAE Technology, Elettronica GF, IpTronix and MAS Elettronica. The Space division operates through Kayser Space, providing technology and support for space exploration activities and microgravity experimentation. Together, the various entities form a technology platform that covers the entire life cycle of a solution: from R&D to co-design, from material supply to prototyping and production and from advanced testing to after-sales support. Founded in 1990 in Gazzaniga (BG) by Francesco Lanza, who began by producing a small series of electronic boards, FAE Technology has been led since 2008 by his son Gianmarco Lanza, current Chairperson and Chief Executive Officer. FAE Technology is known for its focus on innovation - promoting open innovation and shared research at the “Kilometro Rosso” hub - and on sustainability and corporate social responsibility, becoming a Benefit Company on May 13, 2022. FAE Technology benefits from memberships with renowned universities and research centers, including the "Senseable City Lab" at the MIT (Massachusetts Institute of Technology) in

Boston, in addition to strategic partnerships with major sector players. The Group's ability to tap into both organic and acquisition-led growth opportunities, including through supply chain and market consolidation, strengthens its role as a strategic technology development partner to companies and organizations. The Group reported a consolidated value of production in 2025 of Euro 67.6 million.

ISIN FAE Ordinary Shares IT0005500688 - ISIN Warrants WFAE25 IT0005500639

Contacts

FAE Technology S.p.A. - Benefit Company
Investor Relations Manager
Gianmarco Lanza, ir@fae.technology

THANAI Communication Advisors
Press Office
Thanai Bernardini, mob. 335.7245418, me@thanai.it
Alessandro Bozzi Valenti, mob. 348.0090866, alessandro.valenti@thanai.it
Calvin Kloppenburg, mob. 393.1188058, calvin.kloppenburg@thanai.it

Alantra
Euronext Growth Advisor
Tel. +39 3346267243, ega@alantra.com